Literature DB >> 28338660

Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

D Matthew Gianferante1, Lisa Mirabello1, Sharon A Savage1.   

Abstract

Clinical outcomes and treatment modalities for osteosarcoma, the most common primary cancer of bone, have changed very little over the past 30 years. The peak incidence of osteosarcoma occurs during the adolescent growth spurt, which suggests that bone growth and pubertal hormones are important in the aetiology of the disease. Tall stature, high birth weight and certain inherited cancer predisposition syndromes are well-described risk factors for osteosarcoma. Common genetic variants are also associated with osteosarcoma. The somatic genome of osteosarcoma is highly aneuploid, exhibits extensive intratumoural heterogeneity and has a higher mutation rate than most other paediatric cancers. Complex pathways related to bone growth and development and tumorigenesis are also important in osteosarcoma biology. In this Review, we discuss the contributions of germline and somatic genetics, tumour biology and animal models in improving our understanding of osteosarcoma aetiology, and their potential to identify novel therapeutic targets and thus improve the lives of patients with osteosarcoma.

Entities:  

Mesh:

Year:  2017        PMID: 28338660     DOI: 10.1038/nrendo.2017.16

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  189 in total

1.  Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.

Authors:  Martin Köbel; Elise Gradhand; Katharina Zeng; Wolfgang D Schmitt; Karen Kriese; Tilmann Lantzsch; Matthias Wolters; Jürgen Dittmer; Hans G Strauss; Christoph Thomssen; Steffen Hauptmann
Journal:  Int J Gynecol Pathol       Date:  2006-04       Impact factor: 2.762

Review 2.  Osteosarcoma: anatomic and histologic variants.

Authors:  Michael J Klein; Gene P Siegal
Journal:  Am J Clin Pathol       Date:  2006-04       Impact factor: 2.493

Review 3.  ERM proteins and merlin: integrators at the cell cortex.

Authors:  Anthony Bretscher; Kevin Edwards; Richard G Fehon
Journal:  Nat Rev Mol Cell Biol       Date:  2002-08       Impact factor: 94.444

Review 4.  Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.

Authors:  Claudia Maria Hattinger; Massimo Serra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-06-25       Impact factor: 4.481

5.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

6.  A case-control study of osteosarcoma in young persons.

Authors:  E A Operskalski; S Preston-Martin; B E Henderson; B R Visscher
Journal:  Am J Epidemiol       Date:  1987-07       Impact factor: 4.897

7.  Fas expression in lung metastasis from osteosarcoma patients.

Authors:  Nancy Gordon; Carola A S Arndt; Douglas S Hawkins; Debra K Doherty; Carrie Y Inwards; Mark F Munsell; John Stewart; Nadezhda V Koshkina; Eugenie S Kleinerman
Journal:  J Pediatr Hematol Oncol       Date:  2005-11       Impact factor: 1.289

8.  Height at diagnosis and birth-weight as risk factors for osteosarcoma.

Authors:  Lisa Mirabello; Ruth Pfeiffer; Gwen Murphy; Najat C Daw; Ana Patiño-Garcia; Rebecca J Troisi; Robert N Hoover; Chester Douglass; Joachim Schüz; Alan W Craft; Sharon A Savage
Journal:  Cancer Causes Control       Date:  2011-04-05       Impact factor: 2.506

9.  Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model.

Authors:  Ram Mohan Ram Kumar; Matthias Je Arlt; Aleksandar Kuzmanov; Walter Born; Bruno Fuchs
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

10.  The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis.

Authors:  Chand Khanna; Xiaolin Wan; Seuli Bose; Ryan Cassaday; Osarenoma Olomu; Arnulfo Mendoza; Choh Yeung; Richard Gorlick; Stephen M Hewitt; Lee J Helman
Journal:  Nat Med       Date:  2004-01-04       Impact factor: 53.440

View more
  139 in total

1.  S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells.

Authors:  Lu Ding; Rong Li; Rongxin Sun; Yang Zhou; Yubo Zhou; Xiaoping Han; Yong Cui; Wu Wang; Qing Lv; Jingping Bai
Journal:  Cell Cycle       Date:  2017-08-03       Impact factor: 4.534

2.  Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma.

Authors:  Laurie Sorenson; Yanfen Fu; Tressa Hood; Sarah Warren; Troy A McEachron
Journal:  Oncoimmunology       Date:  2019-06-27       Impact factor: 8.110

Review 3.  Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.

Authors:  Ryan D Roberts; Michael M Lizardo; Damon R Reed; Pooja Hingorani; Jason Glover; Wendy Allen-Rhoades; Timothy Fan; Chand Khanna; E Alejandro Sweet-Cordero; Thomas Cash; Michael W Bishop; Meenakshi Hegde; Aparna R Sertil; Christian Koelsche; Lisa Mirabello; David Malkin; Poul H Sorensen; Paul S Meltzer; Katherine A Janeway; Richard Gorlick; Brian D Crompton
Journal:  Cancer       Date:  2019-07-29       Impact factor: 6.860

4.  Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells.

Authors:  Xue-Jing Shao; Sen-Feng Xiang; Ying-Qian Chen; Ning Zhang; Ji Cao; Hong Zhu; Bo Yang; Qian Zhou; Mei-Dan Ying; Qiao-Jun He
Journal:  Acta Pharmacol Sin       Date:  2019-07-11       Impact factor: 6.150

5.  FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.

Authors:  Hanjun Li; Xiuguo Han; Shengbing Yang; Yongjie Wang; Yang Dong; Tingting Tang
Journal:  Oncogene       Date:  2021-03-14       Impact factor: 9.867

6.  Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.

Authors:  Roelof Koster; Orestis A Panagiotou; William A Wheeler; Eric Karlins; Julie M Gastier-Foster; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Adrienne M Flanagan; Roberto Tirabosco; Irene L Andrulis; Jay S Wunder; Nalan Gokgoz; Ana Patiño-Garcia; Fernando Lecanda; Massimo Serra; Claudia Hattinger; Piero Picci; Katia Scotlandi; David M Thomas; Mandy L Ballinger; Richard Gorlick; Donald A Barkauskas; Logan G Spector; Margaret Tucker; D Hicks Belynda; Meredith Yeager; Robert N Hoover; Sholom Wacholder; Stephen J Chanock; Sharon A Savage; Lisa Mirabello
Journal:  Int J Cancer       Date:  2017-12-23       Impact factor: 7.396

7.  Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a.

Authors:  Changhui Li; Shouyun Zhang; Tongguo Qiu; Yuanji Wang; David M Ricketts; Chao Qi
Journal:  Cancer Biol Ther       Date:  2018-11-29       Impact factor: 4.742

8.  Circulating miR-215-5p and miR-642a-5p as potential biomarker for diagnosis of osteosarcoma in Mexican population.

Authors:  Lucero Monterde-Cruz; Eric G Ramírez-Salazar; Genaro Rico-Martínez; Luis M Linares-González; Roberto Guzmán-González; Ernesto Delgado-Cedillo; Eréndira Estrada-Villaseñor; Margarita Valdés-Flores; Rafael Velázquez-Cruz; Alberto Hidalgo-Bravo
Journal:  Hum Cell       Date:  2018-06-15       Impact factor: 4.174

9.  Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.

Authors:  Naser M Ali; Stefania Niada; Anna T Brini; Mark R Morris; Sathishkumar Kurusamy; Abdullah Alholle; David Huen; Cristina R Antonescu; Franck Tirode; Vaiyapuri Sumathi; Farida Latif
Journal:  J Pathol       Date:  2018-12-27       Impact factor: 7.996

10.  Long noncoding RNA NBAT1 negatively modulates growth and metastasis of osteosarcoma cells through suppression of miR-21.

Authors:  Cheng Yang; Guijiang Wang; Jian Yang; Liguo Wang
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.